Clinical trial
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in…
NCT01345019 · Amgen, Industry · Completed
Key facts
| NCT number | NCT01345019 |
|---|---|
| Title | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma |
| Official title | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma |
| Lead sponsor | Amgen, Industry |
| Collaborators | Daiichi Sankyo Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions |
| Intervention type | Drug |
| Interventions | Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase) |
| Enrollment | 1,718 |
| Start date | May 17, 2012 |
| Primary completion | Jul 19, 2016 |
| Completion | Mar 29, 2019 |
| First posted | Apr 29, 2011 |
| Last update posted | Nov 8, 2022 |
| Countries | Australia, Austria, Bulgaria, Canada, Czechia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy and 17 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: